Institute of Clinical Pharmacology, Peking University First Hospital, Beijing 100191, P.R. China.
Department of Hematology, Peking University First Hospital, Beijing 100034, P.R. China.
Int J Mol Med. 2024 Jun;53(6). doi: 10.3892/ijmm.2024.5381. Epub 2024 May 17.
Proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors are widely recognised as being able to induce a potent reduction in low‑density lipoprotein‑cholesterol. An increasing number of studies have suggested that PCSK9 also influences the haemostatic system by altering platelet function and the coagulation cascade. These findings have significant implications for anti‑PCSK9 therapy in patients with specific coagulation conditions, including expanded indications, dose adjustments and drug interactions. The present review summarises the changes in PCSK9 levels in individuals with liver diseases, chronic kidney diseases, diabetes mellitus, cancer and other disease states, and discusses their impact on thrombosis and haemostasis. Furthermore, the structure, effects and regulatory mechanisms of PCSK9 on platelets, coagulation factors, inflammatory cells and endothelial cells during coagulation and haemostasis are described.
前蛋白转化酶枯草溶菌素 9（PCSK9）抑制剂被广泛认为能够强效降低低密度脂蛋白胆固醇。越来越多的研究表明，PCSK9 通过改变血小板功能和凝血级联反应也会影响止血系统。这些发现对抗 PCSK9 治疗特定凝血条件的患者具有重要意义，包括扩大适应证、剂量调整和药物相互作用。本综述总结了肝脏疾病、慢性肾脏病、糖尿病、癌症和其他疾病状态个体中 PCSK9 水平的变化，并讨论了其对血栓形成和止血的影响。此外，还描述了 PCSK9 在凝血和止血过程中对血小板、凝血因子、炎症细胞和内皮细胞的结构、作用和调节机制。
